User Posts: admin3
0
Augtyro ‘Fills a Gap’ in the Treatment of ROS1-Positive NSCLC
0

The next-generation tyrosine kinase inhibitor Augtyro (repotrectinib) represents a new treatment option for patients with locally advanced (cancer that has ...

0
Tooth and Root Damage From Chemotherapy
0

My doctors and nurses always reminded me that chemotherapy kills fast-growing cells, like cancer. Many parts of our body are composed of fast-growing cells, ...

0
Imbruvica-Venclexta Combination Demonstrates Benefits in Untreated CLL
0

The treatment combination of Imbruvica (ibrutinib) and Venclexta (venetoclax) has demonstrated beneficial results regarding progression-free survival (PFS; ...

0
Staying Patient Throughout Someone’s Cancer Journey
0

I was blessed to have good listeners during my cancer journeys. We patients also need to be good at “listening back.”Being a good listener and responder is ...

0
Patients With Cervical Cancer Should Explore Their Fertility Options
0

When receiving a diagnosis of cervical cancer, patients should discuss their fertility options with their care team and be attuned to their mental and ...

0
Scar Tissue Around Pancreatic Tumors May Help Predict Prognosis
0

The scar tissue that forms around pancreatic cancer tumors may offer insight to patient prognosis. The scar tissue that forms around pancreatic cancer ...

0
Side Effects of Bone Strengtheners: Multiple Myeloma
0

When I started taking a bone strengthener, also known as Zometa, could anyone have predicted that a fragment of my jawbone would detach itself from my ...

0
Novel Drug Combo Fast Tracked for Advanced Breast Cancer Subset
0

The Food and Drug Administration (FDA) granted a Fast Track Designation to zotatifin plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for patients ...

0
FDA Approves Jaypirca for Pretreated CLL, SLL
0

The Food and Drug Administration (FDA) granted an accelerated approval to Jaypirca (pirtobrutinib) for the treatment of adults with chronic lymphocytic ...

0
FDA to Speed Up Epkinly Development for Relapsed/Refractory Follicular Lymphoma
0

The Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation to Epkinly (epcoritamab-bysp) for the treatment of patients with relapsed ...

User Deals: admin3
Browsing All Comments By: admin3
CML Alliance
Logo
Enable registration in settings - general
Compare items
  • Total (0)
Compare
0
Shopping cart